Suramin inhibits macrophage activation by human group IIA phospholipase A2, but does not affect bactericidal activity of the enzyme

Inflammation Research

Volumn 58, Issue 4, 2009, Pages 210-217

  Aragao E A ^a   Chioato, L ^a   Ferreira, T L ^a   De Medeiros, A I ^a   Secatto, A ^a   Faccioli, L H ^a   Ward, R J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Inhibitor; Lipid hydrolysis; Membrane permeabilization

Indexed keywords

DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLGLYCEROL; FLUORESCENT DYE; LIPOSOME; NITRIC OXIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP IIA; RECOMBINANT ENZYME; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; FLOW CYTOMETRY; HYDROLYSIS; MACROPHAGE; MACROPHAGE ACTIVATION; MEMBRANE TRANSPORT; MICROCOCCUS LUTEUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANIMALS; ANTINEMATODAL AGENTS; CELL LINE; GROUP II PHOSPHOLIPASES A2; HUMANS; INCLUSION BODIES; MACROPHAGE ACTIVATION; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SURAMIN;

EID: 62949163458     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8137-z     Document Type: Article

References (62)

1. van Deenen LLM, de Haas GH. The substrate specificity of phospholipase A2. Biochem. Biophys. Acta 1963; 70: 538-53.
2. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 2006; 1761: 1246-59.
3. Vadas P, Browning J, Edelson J, Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993; 8: 1-30.
4. Qu XD, Lehrer RI. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect Immun 1998; 66: 2791-7.
5. Harwig SS, Tan L, Qu XD, Cho Y, Eisenhauer PB, Lehrer RI. Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest 1995; 95: 603-10.
6. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol. 1997; 17: 225-83.
7. Laine VJ, Grass DS, Nevalainen TJ. Protection by group II phospholipase A2 against Staphylococcus aureus. J Immunol 1999; 162: 7402-8.
8. Buckland AG, Wilton DC. The antibacterial properties of secreted phospholipases A(2). Biochim Biophys Acta 2000; 1488: 71-82.
9. Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991; 266: 2647-51.
10. Triggiani M, Granata F, Frattini A, Marone G. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 2006; 1761: 1289-300.
11. Ripka WC, Sipio WJ, Galbraith WG. Molecular modeling in the design of phospholipase A2 inhibitors. J Cell Biochem 1989; 40: 279-86.
12. Chandra V, Jasti J, Kaur P, Dey S, Srinivasan A, Betzel C, et al. Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr D Biol Crystallogr 2002; 58: 1813-9.
13. Church WB, Inglis AS, Tseng A, Duell R, Lei PW, Bryant KJ, et al. A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition. J Biol Chem 2001; 276: 33156-64.
14. Mihelich ED, Schevitz RW. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. Biochim Biophys Acta 1999; 1441: 223-8.
15. Kihara H. Studies on phospholipase A in Trimeresurus flaoviridis venom. III. Purification and some properties of phospholipase A inhibitor in Habu serum. J Biochem 1976; 80: 341-9.
16. Nicolas JP, Lambeau G, Lazdunski M. Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor. J Biol Chem 1995; 270: 28869-73.
17. Bernard P, Pintore M, Berthon JY, Chretien JR. A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2. Eur J Med Chem 2001; 36: 1-19.
18. Chandra V, Jasti J, Kaur P, Betzel C, Srinivasan A, Singh TP. First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. J Mol Biol 2002; 320: 215-22.
19. Pentland AP, Morrison AR, Jacobs SC, Hruza LL, Hebert JS, Packer L. Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. J Biol Chem 1992; 267: 15578-84.
20. Lattig J, Bohl M, Fischer P, Tischer S, Tietbohl C, Menschikowski M, et al. Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design. J Comput Aided Mol Des 2007; 21: 473-83.
21. Marcussi S, Sant'Ana CD, Oliveira CZ, Rueda AQ, Menaldo DL, Beleboni RO, et al. Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2007; 7: 743-56.
22. Boilard E, Rouault M, Surrel F, Le Calvez C, Bezzine S, Singer A, et al. Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor. Biochemistry 2006; 45: 13203-18.
23. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993; 85: 611-21.
24. Gradishar WJ, Soff G, Liu J, Cisneros A, French S, Rademaker A, et al. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology 2000; 58: 324-33.
25. Lin-Shiau SY, Lin MJ. Suramin inhibits the toxic effects of presynaptic neurotoxins at the mouse motor nerve terminals. Eur J Pharmacol 1999; 382: 75-80.
26. Arruda EZ, Silva NM, Moraes RA, Melo PA. Effect of suramin on myotoxicity of some crotalid snake venoms. Braz J Med Biol Res 2002; 35: 723-6.
27. de Oliveira M, Cavalcante WL, Arruda EZ, Melo PA, Dal-Pai Silva M, Gallacci M. Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin. Toxicon 2003; 42: 373-9.
28. Othman R, Baker S, Li Y, Worrall AF, Wilton DC. Human nonpancreatic (group II) secreted phospholipase A2 expressed from a synthetic gene in Escherichia coli: characterisation of N-terminal mutants. Biochim Biophys Acta 1996; 1303: 92-102.
29. Ward RJ, de Oliveira AH, Bortoleto RK, Rosa JC, Faca VM, Greene LJ. Refolding and purification of Bothropstoxin-I, a Lys49-phospholipase A2 homologue, expressed as inclusion bodies in Escherichia coli. Protein Expr Purif 2001; 21: 134-40.
30. Richieri GV, Ogata RT, Kleinfeld AM. The measurement of free fatty acid concentration with the fluorescent probe ADIFAB: a practical guide for the use of the ADIFAB probe. Mol Cell Biochem 1999; 192: 87-94.
31. Ferreira TL, Ruller R, Chioato L, Ward RJ. Insights on calciumin-dependent phospholipid membrane damage by Lys49-PLA(2) using tryptophan scanning mutagenesis of bothropstoxin-I from Bothrops jararacussu. Biochimie 2007.
32. Lane TE, Wu-Hsieh BA, Howard DH. Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state. Infect Immun 1993; 61: 1468-73.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
34. Scott DL, White SP, Browning JL, Rosa JJ, Gelb MH, Sigler PB. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science 1991; 254: 1007-10.
35. Baker SF, Othman R, Wilton DC. Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. Biochemistry 1998; 37: 13203-11.
36. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, et al. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002; 277: 48535-49.
37. Jancar S, Sanchez Crespo M. Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol 2005; 26: 48-55.
38. Suschek CV, Schnorr O, Kolb-Bachofen V. The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? Curr Mol Med 2004; 4: 763-75.
39. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
40. Terenzi F, Diaz-Guerra MJ, Casado M, Hortelano S, Leoni S, Bosca L. Bacterial lipopeptides induce nitric oxide synthase and promote apoptosis through nitric oxide-independent pathways in rat macrophages. J Biol Chem 1995; 270: 6017-21.
41. Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005; 7: 1251-62.
42. Beers SA, Buckland AG, Koduri RS, Cho W, Gelb MH, Wilton DC. The antibacterial properties of secreted phospholipases A2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem 2002; 277: 1788-93.
43. Mortimer FC, Mason DJ, Gant VA. Flow cytometric monitoring of antibiotic-induced injury in Escherichia coli using cell-impermeant fluorescent probes. Antimicrob Agents Chemother 2000; 44: 676-81.
44. Cherry JK. The treatment of onchocerciasis. East Afr Med J 1960; 37: 550-8.
45. Schneider J. [Treatment of human African trypanosomiasis.]. Bull World Health Organ 1963; 28: 763-86.
46. Arbuck SG, Sorensen JM, Christian MC, Ho P, Pluda JM, Cheson BD. New drugs in non-Hodgkin's lymphoma. Ann Oncol 1997; 8 Suppl 1: 119-28.
47. Ahles TA, Herndon JE, 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, et al. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer 2004; 101: 2202-8.
48. Lu Z, Wientjes TS, Au JL. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res 2005; 22: 1069-78.
49. Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg 2007; 11: 171-8.
50. Zhu XB, Tang SB, Luo Y, Huang XK. [The inhibiting effects of suramin on bFGF induced proliferation of cultured human RPE cells.]. Zhonghua Yan Ke Za Zhi 2005; 41: 110-3.
51. Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, Hohenegger M, et al. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol 1996; 49: 602-11.
52. Freissmuth M, Waldhoer M, Bofill-Cardona E, Nanoff C. G protein antagonists. Trends Pharmacol Sci 1999; 20: 237-45.
53. Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, Fischer MJ, Janssen LH, et al. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop 1993; 54: 237-50.
54. Murakami MT, Vicoti MM, Abrego JR, Lourenzoni MR, Cintra AC, Arruda EZ, et al. Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. Toxicon 2007; 49: 378-87.
55. Chioato L, Aragao EA, Lopes Ferreira T, Ivo de Medeiros A, Faccioli LH, Ward RJ. Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A(2) by scanning alanine mutagenesis. Biochim Biophys Acta 2007; 1768: 1247-57.
56. Sà JM, Chioato L, Ferreira TL, De Oliveira AH, Ruller R, Rosa JC, et al. Topology of the substrate-binding site of a Lys49-phospholipase A2 influences Ca2+-independent membrane-damaging activity. Biochem J 2004; 382: 191-8.
57. Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Elias S, Tomaz MA, et al. Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. J Mol Biol 2005; 350: 416-26.
58. Pieterson WA, Vidal JC, Volwerk JJ, de Haas GH. Zymogen-catalyzed hydrolysis of monomeric substrates and the presence of a recognition site for lipid-water interfaces in phospholipase A2. Biochemistry 1974; 13: 1455-60.
59. Snitko Y, Yoon ET, Cho W. High specificity of human secretory class II phospholipase A2 for phosphatidic acid. Biochem J 1997; 321 ( Pt 3): 737-41.
60. Baek SH, Lim JH, Park DW, Kim SY, Lee YH, Kim JR, et al. Group IIA secretory phospholipase A(2) stimulates inducible nitric oxide synthase expression via ERK and NF-kappaB in macrophages. Eur J Immunol 2001; 31: 2709-17.
61. Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 2002; 531: 2-6.
62. Chang YC, Li PC, Chen BC, Chang MS, Wang JL, Chiu WT, et al. Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways. Cell Signal 2006; 18: 1235-43.